Author/Authors :
Wu Wenjun نويسنده , Gao Haibing نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Lin Shenglong نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Lv Xujiang نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Ma Huaxi نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Wang Xiangmei نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Fang Jiankai نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Lin Jiahuang نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Chen Xiumin نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China , Lin Minghua نويسنده Mengchao Hepatobiliary Hospital of Fujian Medical
University, Fujian, China
Abstract :
Introduction Benign recurrent intrahepatic cholestasis (BRIC) is a
rare autosomal recessive disease characterized by recurrent episodes of
severe pruritus and jaundice. Although the disease symptom will relieve
spontaneously without leaving any hepatic injury, the ceaseless attacks
would reduce the life quality of patients. However, there is not a
validated treatment for BRIC yet. Considering the limited cases and the
unpredictability of this disease, the publications of well-described
case reports are necessary for the investigation of disease development
and treatment efficacy. Case Presentation A 26-year-old Chinese male,
with clinical approved and genetic diagnosis of BRIC, experienced 3
attacks of recurrent intrahepatic cholestasis from 2010 to 2016. During
hospitalizations, he received symptomatic treatments and plasmapheresis
therapies. Both plasma exchange (PE) and plasma bilirubin adsorption
(PBA) were conducted for him. The whole-exome sequencing revealed
several single nucleotide polymorphisms (SNPs) as well as 2 novel
mutations in ABCB11 (c.70A > T, p.Lys24*, exon2 and c.1417G
> A, p.Asp473Asn, exon13). These SNPs and mutations might be
associated with the BRIC development. Conclusions Both medications and
plasmapheresis interventions could relieve the patient’s symptoms,
however, neither could shorten the natural process of the disease. The 2
mutations (c.70A > T and c.1417G > A) in ABCB11 were first
reported in a BRIC patient.